TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Orthocell Ltd ( (AU:OCC) ) has shared an update.
Orthocell Limited has increased its equity stake in Marine Biomedical Pty Ltd to 12%, securing global distribution rights for PearlBone™, an innovative bone substitute made from sustainably sourced pearl shells. This strategic investment enhances Orthocell’s regenerative medicine portfolio and positions the company to capitalize on the US$1.6 billion bone substitute market, with expectations of significant value growth following regulatory approvals.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company specializing in biologically driven solutions for nerve, tendon, and bone repair. The company focuses on leveraging its established distribution networks, particularly in the United States, to deliver innovative medical products to the market.
Average Trading Volume: 633,878
Technical Sentiment Signal: Buy
Current Market Cap: A$324.7M
See more insights into OCC stock on TipRanks’ Stock Analysis page.